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Background: Despite successful implementation of drugs targeting the human epidermal growth factor receptor 2 (HER2)
receptor in breast and gastric cancers, the potential of HER2 as a therapeutic target in other cancers has been less studied,
including endometrial cancer. We investigated expression levels of HER2 (ERBB2) in a large cohort of endometrial cancer lesions,
also including complex atypical hyperplasia and metastatic lesions.
Methods: 67 precursor lesions, 790 primary endometrial cancers and 383 metastatic lesions were investigated for HER2 expression
in relation to clinicopathologic features and outcome. Protein levels were assessed by immunohistochemistry (using the
HercepTest and staining index (SI) criteria), mRNA levels by microarrays and amplification status by chromogenic in situ
hybridisation.
Results: High HER2 protein levels were significantly associated with features of aggressive disease and increased mRNA ERBB2
levels. HER2 expression defined by the SI proved to be a better predictor of survival compared with the HercepTest. A discordant
HER2 expression pattern between paired primary and metastatic lesions was detected, revealing substantial reduction in HER2
expression from primary to metastatic disease.
Conclusions: Loss of HER2 expression is common in metastatic endometrial cancer lesions and assessment of HER2 levels in the
metastatic lesions may be important to define the potential benefit of anti-HER2 treatments in endometrial cancer patients.
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Endometrial cancer is the most frequent gynaecologic malignancy
in industrialised countries (Torre et al, 2015), yet the progress of
implementing tailored treatment for women with advanced and
recurrent disease is slow. The primary treatment for endometrial
cancer patients is hysterectomy and bilateral salpingoophorectomy.
Thus, adjuvant treatment is directed toward any remaining
metastatic tissue. Chemotherapy is currently the standard treat-
ment for systemic recurrent/metastatic endometrial cancer, yet the
response rates are low and overall survival is short (Fleming, 2015).
In the era of individualised cancer therapy, biomarkers for
treatment of metastatic disease are needed.
Proteins expressed on the surface of tumour cells can be
selectively targeted, and one of the most frequently targeted
proteins is the human epidermal growth factor receptor 2 (HER2),
a well-characterised receptor anchored to the cell membrane coded
by the gene ERBB2. Amplifications in ERBB2 have been linked to
response to HER2-targeting agents such as the monoclonal
antibodies trastuzumab and lapatinib, which has revolutionised
treatment of HER2-positive breast cancer (Ahmed et al, 2015).
HER2-inhibiting compounds are currently being tested in a broad
range of cancer types. Case report studies have confirmed clinical
activity of trastuzumab in recurrent endometrial carcinoma in vivo
(Jewell et al, 2006; Villella et al, 2006; Santin et al, 2008), yet
trastuzumab as single agent showed no significant benefit in a
phase II clinical trial with HER2-overexpressing tumours (Fleming
et al, 2010). Lack of proper pre-selection of patients with ERBB2
amplification and/or HER2 overexpression could partly explain the
poor clinical activity observed in HER2-directed trials with
endometrial cancer patients (Santin, 2010; Leslie et al, 2012).
Strategies combining trastuzumab with other agents are under
development, and may prove to be more efficient than single-agent
trastuzumab in endometrial cancer treatment. Endometrial serous
carcinomas, a biological aggressive subtype of endometrial cancer,
are known to exhibit high levels of ERBB2 amplification (17–47%,
(Slomovitz et al, 2004; Santin et al, 2005; Cancer Genome Atlas
Research N et al, 2013; Growdon et al, 2015; Jones et al, 2015)) and
HER2 overexpression (14–80% (Buza et al, 2014; Jones et al,
2015)). High rates of resistance to conventional therapy are
reported for the serous cancers, and the development of new
treatment strategies is therefore important.
In breast cancer, both retrospective and prospective studies
indicate a substantial discrepancy in HER2 status between primary
and recurrent cancer lesions (Amir et al, 2012; Vignot et al, 2012),
and recently the assessment of HER2 status in recurrent/metastatic
breast cancer lesions has been added to Advanced Breast Cancer
consensus guidelines (Cardoso et al, 2017). HER2 status in primary
endometrial cancer tissue is well characterised, yet so far,
relationships between HER2 status in primary and associated
metastatic lesions are not documented. The aim of this study was
to investigate HER2 status in a large prospective series of complex
atypical hyperplasia (CAH), primary tumours and metastatic
lesions including endometrioid, serous, carcinosarcomas, clear cell
and undifferentiated carcinomas. To evaluate the relevance of
HER2 as a target for patients with metastatic or recurrent
endometrial cancer, HER2 expression in metastatic lesions was
characterised and compared with corresponding primary tumour
lesions. To our knowledge, this is the first comprehensive study
describing HER2 status in paired primary and metastatic
endometrial cancers.
MATERIALS AND METHODS
Ethics statement. This study was approved by the Norwegian
legislation and research permission and was granted by the
Norwegian Social Data Service (15501), the Western Regional
Committee for Medical and Health Research Ethics and regional
Institutional Review Board (IRB 2009-2315). Participants gave
informed written consent.
Patient samples. A population-based patient series including 790
patients diagnosed with primary endometrial cancer were
prospectively collected in a population based setting in Hordaland
County (Norway) from 2001 to 2015. Patient age, stage of disease,
histologic type, histologic grade, recurrence status, DNA ploidy
status, myometrial infiltration, treatment and follow-up were
obtained from the clinical records. The median follow-up for
survivors was 48 months (range 0–147). A series of 67 endometrial
CAH was prospectively collected from 2001–2012. Clinical
information was collected as for the endometrial cancer patients,
yet no follow-up data were available from patients with CAH.
Oestrogen receptor (ER) and progesterone receptor (PR) was
stained and scored as previously described (Engelsen et al, 2008a;
Krakstad et al, 2012; Tangen et al, 2014). Formalin-fixed paraffin-
embedded (FFPE) tissue from hysterectomy specimens and
metastatic biopsies were assessed and mounted in TMAs as
previously described (Engelsen et al, 2008b). FFPE tissue from
metastatic biopsies was available from 192 patients (in total 383
lesions). All patients were staged according to the current
International Federation of Gynecology and Obstetrics staging
system (Pecorelli, 2009). The TMA method has previously been
described and validated in several studies (Kononen et al, 1998;
Hoos et al, 2001; Stefansson et al, 2004). In brief, areas with the
highest tumour grade and purity were selected on haematoxylin
and eosin-stained slides. Tissue cylinders (0.6 mm) (three from
primary tumours and CAH and one to three from metastatic
lesions) were punched from selected areas and mounted into a
recipient paraffin block using a custom-made precision instrument
(Beecher instruments, Silver Spring, MD, USA).
Immunohistochemical staining of HER2. Immunohistochemical
(IHC) staining of HER2 was performed on TMA sections (5 mm),
which were dewaxed with xylene, rehydrated in graded ethanol and
boiled for 15 min for antigen retrieval in target retrieval solution
(pH 9, Dako, Glostrup, Denmark). Sections were blocked for
peroxidase activity (S2023, Dako) and incubated for 1 h at room
temperature with polyclonal anti-HER2 antibody (A 0485, Dako)
diluted 1 : 400. Secondary HPR-conjugated antibody was applied
for 30 min in room temperature followed by Diaminobenzidine (K
4010, Dako) for 8 min. Counterstaining with haematoxylin was
performed before dehydration and mounting.
Evaluation of staining. The sections were scored according to the
HercepTest criteria and in line with the updated recommendations
for HER2 assessment in breast cancer (Wolff et al, 2013; Rakha
et al, 2015) on a scale from 0 to 3þ : no staining or membrane
staining in o10% (0), faint partial staining in 410% (1þ ), weak
to moderate (2þ ) or strong (3þ ) staining of the entire membrane
in 410% of the tumour cells. Only membrane staining of the
invasive tumour was evaluated, and cytoplasmic staining was
considered non-specific and not included in this scoring As
negative control, we used normal tissue known not to express
HER2, such as connective tissue adjacent to the tumour cells.
When 74 cases were scored independently by two individual
researchers (MKH and ILT) the inter-observer value was very good
(kappa value¼ 0.89) for the HercepTest Score using two categories
(3þ vs o3þ ) and good (kappa value¼ 0.74) using four
categories. HercepTest Score 2þ was defined as moderate and
3þ as high HER2 expression. When evaluating multiple
metastatic lesions from the same patient with divergent HercepTest
Score, the lesion(s) with the highest HercepTest Score was selected
for comparison.
Simultaneously, all TMA sections were evaluated by the semi-
quantitative, staining index (SI), where both intensity of the
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staining and portion of positive tumour cells were considered. The
SI is a well-established scoring method (Engelsen et al, 2008a) that
has previously been used for several biomarkers and in several
tumour types (Aas et al, 1996; Bachmann et al, 2006; Lin et al,
2008). Staining intensity was classified from 0 (no staining) to 3
(strong staining). Quantity of stained tumour cells was classified as
0, 1 (o10%), 2 (10 to 50%) and 3 (450%). SI was defined as the
product of intensity and staining area as previously described. The
inter-observer agreement was good (kappa¼ 0.79) using two
categories (0–6 vs 9) and within all categories (kappa¼ 0.68)
within the 74 cases scored individually by two researchers (M.K.H
and I.L.T).
In addition, HER2 levels assessed by the HercepTest, were re-
evaluated in relation to apical staining patterns in 764 primary
tumours. The tumours were classified according to presence of
apical HER2 membrane staining as either ‘apical HER2 loss’ or
apical loss ‘not detected’. To evaluate if apical loss affected the
prognostic value of the HercepTest, tumours with strong lateral/
basolateral staining and apical loss were reclassified as 3þ
tumours. However, the classical HercepTest criteria were followed
in all subsequent analyses.
Chromogenic in situ hybridisation. ERBB2 gene amplification
status was analysed on TMA sections (5 mm) using chromogenic
in situ hybridisation (CISH). This is an established method in
breast cancer treatment for detecting amplified ERBB2. Included in
the analysis were 169 metastatic lesions with overlapping IHC
results. The CISH assays were run at the Department of Pathology,
University of Bergen following the manufacturer’s protocol
(BenchMark Ultra, Ventana Medical Systems, Tucson, Arizona).
The CISH evaluations were performed blinded and without
knowledge of HER2 scoring from IHC. For each cancer lesion,
visible gene probe signals were counted in 20 nuclei by standard
light microscopy, and mean ;gene probe signals per cell were
calculated and defined as absolute gene copy number. In line with
the American Society of Clinical Oncology (ASCO)/College of
American Pathologists (CAP) guideline recommendations normal
copy number was defined as an absolute ERBB2 copy number o4,
borderline amplification as 4–6 and amplified ERBB2 as six gene
copies or more (Wolff et al, 2013).
Gene expression analyses. Fresh tissue for RNA extraction was
available for 184 of the primary tumours. RNA was extracted using
the RNeasy Mini Kit (Qiagen, Hilden, Germany) followed by
hybridisation onto Agilent Whole Human Genome Microarrays 44
k (Cat. No G4112F). Signal intensities were defined using the
software J-express (Molmine, Bergen, Norway) (www.molmine.-
com) (Dysvik and Jonassen, 2001), and median spot intensity was
used to determine intensity of signals. The data set included
expression values for genes represented by 41 001 probes and
expression data were quantile normalised.
Statistical analysis. The data were analysed by the software
package SPSS (Statistical Package of Social Science) version 24
(IBM, Armonk, NY, USA). Weighted kappa was used to assess
inter-observer agreement value when categories were ordered. All
P-values are two-sided and considered statistically significant if
o0.05. Associations between groups were analysed with Person w2,
linear-by-linear-association or Fisher’s exact test for categorical
variables, and the Mann–Whitney U-test for continuous variables
as appropriate. Univariate survival analysis of death due to
endometrial cancer (disease-specific survival; DSS) was performed
using the Kaplan–Meier (product-limit) method, and differences in
survival between groups were calculated by the log-rank test
(Mantel–Cox).
RESULTS
High HER2 expression associates with aggressive disease and
poor survival in primary endometrial cancer. HER2 expression
was detected by IHC and evaluated by the HercepTest and the SI
criteria. For evaluation using the HercepTest criteria, FDA
guidelines were followed and only membranous staining was
considered (Supplementary Figure 1). High HER2, defined as
HercepTest Score 3þ was significantly associated with established
markers of aggressive disease (Table 1) and poor outcome
(Figure 1A). The 5-year DSS for patients with primary tumours
with low HER2 expression (0–2þ ) was 87, vs 77% for patients
with HER2-high expressing tumours (3þ ) (P¼ 0.006, Figure 1A).
mRNA levels of ERBB2 was positively correlated to protein levels
of HER2 measured by the HercepTest criteria in 184 overlapping
samples (P¼ 0.01, Figure 1B). A gradual increase in number of
HER2 high tumours was observed according to aggressiveness of
histologic type and grade (Figure 1C, Po0.001, trend test). The
highest proportion of high HER2 (3þ ) was found among serous
tumours (49%), followed by clear celled (30%), carcinosarcomas
Table 1. Main clinicopathologic features in relation to HER2








Variables (n)a n (%) n (%)
Age (n¼790) o0.001c
Mean age 64 70
FIGO-09 staged (n¼ 790) 0.04
I–II 561 (84) 105 (16)
III–IV 95 (77) 29 (23)
Histologic type (n¼ 790) o0.001
Endometrioid 561 (88) 80 (12)
Serous papillary 37 (51) 35 (49)
Clear cell 21 (70) 9 (30)
Carcinosarcoma 26 (77) 8 (23)
Undifferentiated 11 (85) 2 (15)
Histologic gradee (n¼623) 0.003
Grade ½ 458 (89) 55 (11)
Grade 3 87 (79) 23 (21)
Recurrence (n¼ 789) 0.03
No recurrence 518 (85) 92 (15)
Metastatic at primary 41 (75) 14 (25)
Later recurrence 96 (77) 28 (23)
DNA ploidy (n¼ 500) o0.001
Diploid 335 (87) 52 (13)
Aneuploid 82 (73) 31 (27)
Myometrial infiltration (n¼ 788) 0.66
o50% 403 (83) 80 (17)
450% 250 (82) 54 (18)
ER (n¼ 649) 0.99
Positive 410 (85) 73 (15)
Negative 141 (85) 25 (15)
PR (n¼ 647) 0.006
Positive 434 (87) 65 (13)
Negative 115 (78) 33 (22)
Abbreviations: ER¼oestrogen receptor; PR¼progesterone receptor.
an¼ number of cases with available data for each variable.
bPearson’s chi-square test (asymp sig. two-sided).
cMann–Whitney U-test for independent samples.
dFIGO: The Féderation Internationale de Gynécologie et d’Obstétrique.
eOnly endometrioid histology.
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(23%), endometrioid grade 3 (21%), grade 2 (12%) and grade 1
(10%) tumours. Within the investigated CAH, 4% exhibited high
HER2 levels (Figure 1C). In multivariate survival analysis, high
HER2 (measured by the HercepTest) and ERBB2 mRNA levels
were not associated with poor survival when correcting for age,
stage and grade (Supplementary Table 1A and B, respectively).
To investigate whether the scoring criteria for detecting HER2-
positive endometrial cancers could be improved, an alternative
method, the SI for evaluation of IHC was applied. When the SI
criteria were used, cytoplasmic staining was included in the
evaluation. Based on observed differences in univariate survival
analysis according to the SI criteria, high HER2 was defined as SI 9
and SI 0–6 as HER2 low (Supplementary Figure 2A). High HER2
(SI 9) was significantly associated with markers for aggressive
disease (Supplementary Table 2) and survival (Figure 2A). In
univariate survival analysis, patients with low HER2 (SI 0–6)
tumours had a 5-year DSS of 87, vs 61% for patients with high
HER2 (SI 9) tumours (Po0.001, Figure 2A). A strong positive
correlation between the HER2 protein levels assessed by the SI
criteria and ERBB2 mRNA expression was observed (P¼ 0.002,
Supplementary Figure 2B). Considering the strong prognostic
impact of this alternative scoring method (SI) compared with the
more established HercepTest, we performed survival analyses,
using SI criteria, within subgroups of patients with known poor
survival and treatment response. High HER2 (SI 9) was associated
with poor outcome within ER- and/or PR-negative tumours
(P¼ 0.008, Supplementary Figure 2C) and within non-endome-
trioid tumours (P¼ 0.03, Supplementary Figure 2D). These
patients were not identified using the HercepTest criteria (data
not shown). Interestingly, also within HercepTest Score 3þ
tumours, High HER2 SI (SI 9) associated with poor outcome
compared with SI 0–6 (P¼ 0.003, Figure 2B). In multivariate
survival analysis corrected for age, stage and grade, High HER2 (SI
9) independently associated with survival, although not significant
(HR 1.61 (95% CI: 0.91–2.85, P¼ 0.1), Supplementary Table 1C).
Lack of apical HER2 membrane staining resulting in basolateral/
lateral staining patterns has previously been described in serous
endometrial carcinomas (Buza et al, 2013). We carefully examined
staining patterns to investigate whether this affects the prognostic
impact of HER2. Lack of apical staining was observed in 45% of the
primary tumours. Staining patterns are exemplified in Figure 2C
(full membrane staining) and Figure 2D (loss of apical staining). A
significant difference in apical staining patterns was observed
among different histologic groups (P¼ 0.03, Supplementary
Table 3). The serous tumours (Figure 2C and D, right panel)
had the highest prevalence of apical HER2 loss (64%) followed by
clear cell carcinomas (46%), endometrioid carcinomas (44%),
undifferentiated tumours (38%) and carcinosarcomas (33%)
(Supplementary Table 3). Reclassifying tumours with loss of apical
HER2 staining and strong lateral/basolateral membranous staining
pattern into HercepTest 3þ Score (P¼ 0.039, Figure 2E) did not
affect overall survival compared with results from the HercepTest
criteria (P¼ 0.036, Figure 2F), indicating that these cases could be
scored as 3þ when evaluating HER2 staining.
Divergent HER2 expression patterns in primary and corre-
sponding metastatic lesions. HER2 expression levels in primary
and associated metastatic lesions were compared according to the
established HercepTest criteria (Figure 3A and B, n¼ 142). Of the
primary tumours with corresponding metastatic lesions, 11%
(9/81) of the endometrioid tumours and 41% (25/61) of the non-
endometrioid tumours had high HER2 levels (3þ ). Among the
non-endometrioid tumours, 57% (35/61) were serous and in these
57% (20/35) had HER2-high levels (3þ ) and 31% (11/35) had
intermediate HER2 levels (2þ ) (Figure 3B).
In the endometrioid paired primary and metastatic cases, a
decrease in lesions with high HER2 was found for metastatic sites
(n¼ 7) as compared with the primary sites (n¼ 9) (Figure 3A). For
non-endometrioid metastatic lesions (Figure 3B), the highest
percentage of HER2-high (3þ ) was found within the serous
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Figure 1. Relationship between HER2 expression (assessed by the
HercepTest) and survival, mRNA expression and aggressiveness of
disease. Kaplan–Meier curves representing endometrial carcinoma
disease-specific survival (DSS) according to HER2 protein levels,
assessed by the HercepTest criteria (A). ERBB2 mRNA expression in
tumours with increasing HercepTest Score (B). Proportion of HER2
overexpression (3þ ) with increasing disease aggressiveness, also
including complex atypical hyperplasia (C). CAH = Complex atypical
hyperplasia, CC = Clear cell carcinoma, CS = Carcinosarcoma, G1 =
Grade 1, G2 = Grade 2, G3 = Grade 3, S = Serous carcinoma.
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primary tumours retained high HER2 levels in the metastatic
setting. Among the serous primary tumours with low HER2 (0–
2þ ) (n¼ 15), three patients had HER2-high metastatic lesions.
For patients with carcinosarcoma, the number of HER2-high
tumours increased from three to five from the primary to the
metastatic setting. In clear cell carcinomas, a small fraction of
HER2-high lesions was found both in primary and metastatic
lesions. In undifferentiated tumours, one primary and no
metastatic lesions were HER2-high (Figure 3B). Altogether, high
HER2 levels were found in 18% (25/142) of the metastases
investigated. Within the HER2-high primary tumours, 62% (21/34)
had HER2-low corresponding metastatic lesions; and within the
HER2-low primary tumours, only 11% (12/108) had HER2-high
corresponding metastases (Table 2). Overall, discordant expression
of HER2 (HercepTest 0–2þ vs 3þ ) between primary and
corresponding metastatic lesion(s) was observed in 23% (33/142)
of the patients, with similar rates for patients treated with chemo-
and/or radiation therapy between primary and recurrent disease
(data not shown). Interestingly, within cases with available
multiple metastatic lesions, 16% (10/62) had divergent HER2
expression levels (0–2þ vs 3þ ) within the different metastatic
sites evaluated (Figure 3).
For patients with few treatment options, expression of HER2
may open for targeted therapy also when expression levels are
lower than HercepTest Score 3þ . If a HercepTest Score 2þ is
found to be sufficient for effective HER2-directed treatment in
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Figure 2. Disease-specific survival (DSS) according to the staining index (SI) criteria and apical HER2 loss. Low HER2 represents SI 0–6 and High
HER2 represents SI 9. Kaplan–Meier curves representing endometrial carcinoma DSS according to HER2 protein levels assessed by the SI criteria
(A). DSS according to HER2 assessed by the SI criteria for patients with HercepTest Score 3þ tumours (B). Tumours with complete HER2
membrane staining (C) and HER2 apical loss (D) in endometrioid (EEC; left) and serous (S; right) tumours. DSS according to the HercepTest after
re-evaluation of HER2 scoring considering apical loss in four groups (E). DSS according to the original FDA HercepTest criteria in four groups (F).
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metastatic endometrial cancer, 40 additional patients (28%)
included in this cohort could potentially benefit from such
treatment regime, 65 (36%) patients in total.
The HercepTest scoring criteria sensitively predict ERBB2
amplification in metastatic endometrial cancer lesions. Relation
between amplification status and protein expression were
investigated in a subset of the metastatic lesions (n¼ 169). A
positive correlation between increasing ERBB2 copy number and
HER2 protein levels obtained from the HercepTest (Po0.001,
Figure 4A) and the SI criteria (P¼ 0.005, Figure 4B) was found.
To test which of the two IHC scoring methods could predict
ERBB2 amplification status most accurately, the specificity and
sensitivity of the two methods in predicting amplification status of
ERBB2 was calculated. Borderline amplification was not considered
in the sensitivity and specificity calculations. A HercepTest
Score 3þ identified 10 of 11 (91%) lesions found to be amplified
by CISH, whereas SI 9 only detected 4 of 11 amplified lesions
(36%) (Supplementary Table 4A, Figure 4C). However, among
lesions with normal copy number by CISH, 18 of 144 (12%) scored
3þ and only 1 of 144 (0.7%) scored SI 9% (Supplementary
Table 4A, Figure 4D). Based on these numbers, the HercepTest
criteria had a sensitivity of 91% and a specificity of 88% in
predicting amplification status of ERBB2 in metastatic lesions,
whereas the sensitivity and specificity of SI scoring method were
36% and 99.3%, respectively (Supplementary Table 4B). The
positive and negative predictive value of the HercepTest was 36
and 99%, and for SI 80 and 96%, respectively (Supplementary
Table 4B). Although many false positives, the HercepTest criteria
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Figure 3. Expression patterns in HER2 metastatic lesions compared with the primary tumour. HER2 expression of the individual metastatic lesion
compared with its expression in in primary tumour in endometrioid (A) and non-endometrioid (B) cases. MET(s) = Metastasis or Metastases, PT =
primary tumour, Undiff = Undifferentiated tumour.
Table 2. Comparison of HER2 status assessed by the
HercepTest criteria in 142 primary and matched metastatic
sites
HercepTest score in metastatic sites
0 1þ 2þ 3þ Total
n (%) n (%) n (%) n (%) n (%)
HercepTest score in primary sites
0 8 (35) 8 (35) 5 (22) 2 (8) 23 (16)
1þ 17 (49) 10 (29) 5 (14) 3 (8) 35 (24)
2þ 15 (29) 21 (40) 9 (17) 7 (14) 50 (36)
3þ 4 (12) 12 (35) 5 (15) 13 (38) 34 (24)
Total 44 (31) 51 (35) 24 (17) 25 (17) 142 (100)
n¼number of cases with available data for each variable. Total number in each group is
given in bold.
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DISCUSSION
HER2 activation initiate signal transduction through the mitogen-
activated protein kinase and PI3K signalling leading to transcrip-
tion of genes that promote oncogenic transformation via cell
survival, proliferation, angiogenesis and metastasis (Yarden and
Sliwkowski, 2001). Amplification in ERBB2, the gene coding for
HER2, is a genomic alteration associated with high-risk endome-
trial carcinomas (Cancer Genome Atlas Research N et al, 2013;
Salvesen et al, 2009, 2012; Jones et al, 2017), and distinct subsets of
high-risk endometrial cancer patients could be potential candidates
for HER2-directed treatment. To the best of our knowledge, this is
the largest population-based endometrial cancer cohort investigat-
ing HER2 expression. We find high HER2 (3þ ) in 16% of primary
tumours. A considerable variability in reported HER2 expression
rates exists (Buza et al, 2014). This is at least partly owing to
variability in testing methods, interpretation, and scoring criteria
applied. Contrasting breast and gastric cancer, no established
HER2 testing guidelines exist in endometrial cancer, and refined
and more standardised testing protocols for each cancer type are
needed to identify patients that may benefit from HER2-directed
treatment. To deal with HER2-testing challenges, an alternative
scoring method, the SI was evaluated. Patients with very poor
survival were identified using high HER2 (SI 9), even in subgroups
of ER and/or PR negative, non-endometrioid and HercepTest 3þ
tumours. Although fewer patients were identified with SI 9 than
with HercepTest Score 3þ , this alternative scoring method yields
as a strong prognostic marker in HER2-high patients. When re-
evaluating the primary tumours included on TMAs we observed
some degree of loss of apical HER2 staining in 45% of the tumours.
Within different histologic types, significant differences in the
prevalence of this pattern were detected, and loss of apical staining
was most often observed in serous tumours (64%) in line with
previous findings (Buza et al, 2013). When allowing tumours with
strong lateral/basolateral staining and apical HER2 loss for a 3þ
score, no effect was seen on survival, indicating that also these
patients should be included in the 3þ group in guidelines for
HER2 evaluation in endometrial cancer. The present study
explores HER2 expression using TMAs, and not full sections.
The TMA method enables high-throughput, cost and time effective
analysis and reduces the amount of tissue used as well as potential
batch effects during staining. However, selected areas may not be
representative of the entire tumour. Although TMA is a very useful
tool in a research setting, optimal cutoff values for markers
explored by IHC, FISH or CISH should be validated using full
sections before clinical implementation.
The current study cohort included 641 endometrioid, 72 serous
and 30 clear cell carcinomas, 34 carcinosarcomas and 13
undifferentiated tumours. Distinct differences in HER2 expression
between the histologic types were discovered. Serous carcinomas,
clear cell carcinomas, carcinosarcomas and high-grade endome-
trioid carcinomas had the highest proportions of tumours
exhibiting high HER2 (3þ ) (in 49%, 30%, 23% and 21%,
respectively), contrasting low-grade endometrioid tumours, with
only 11%. This is in line with previous studies in endometrial
cancer, and supportive of our finding that HER2 is associated with
aggressive disease (Slomovitz et al, 2004; Morrison et al, 2006;
Jones et al, 2017). Patients with non-endometrioid and high-grade
endometrioid tumours are in need of improved and more targeted
therapeutic strategies, and our study confirms that HER2-directed
treatment could represent a potential option for subsets of these
patients.
Systemic treatment in endometrial cancer is predominantly
aimed towards metastatic and recurrent disease. Hence, knowledge
of metastatic HER2 levels is essential to identify endometrial cancer
patients suitable for HER2-directed treatment. This is to date the
largest characterisation of HER2 expression in metastatic endo-
metrial cancer. Comparable to what is found in breast cancer
(Niikura et al, 2012; Criscitiello et al, 2014; Shachar et al, 2017), we
find a heterogeneous HER2 expression pattern between primary
and corresponding metastatic lesion(s). Our results, based on IHC
assessment of HER2, show that conversion from HER2-high (3þ )
HER2-low (0–2þ ) status is higher than the opposite conversion
(62% vs 11%, respectively). Especially, within the HER2-high-rich
clear cell and serous primary tumours, HER2 overexpression
decreased from primary to metastatic setting. If selection of
patients is based on HER2 expression in primary tumours, this
could partly explain the modest response to HER2-targeted
treatment reported in the NCT00006089/GOG181B clinical trial
with endometrial cancer patients (Fleming et al, 2010). Although
technical issues, including poor reproducibility of the staining and
scoring of HER2 may explain some of the observed divergence
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Figure 4. Comparison of HER2 levels assessed by
immunohistochemistry (HercepTest and staining index) and absolute
copy number (absCN) detected by chromogenic in situ hybridisation.
AbsCN in tumours with increasing HercepTest Score (A) and Staining
Index (B) in metastatic lesions. Metastatic lesion with HER2
overexpression (HercepTest 3þ /SI 9) and amplified ERBB2 (absCN of
15.2) (C) or no amplification in ERBB2 (abs 2.0) (D).
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heterogeneity can be another part of the explanation. Recent
studies based on next-generation sequencing of endometrial cancer
tissue (Gibson et al, 2016) supports the hypothesis of tumour
heterogeneity and sub clonal genetic tumour evolution may lead to
variation in, for example, HER2 status in primary and metastatic
sites. In line with this, our study has revealed discordant HER2
expression between different metastases obtained from the same
patients. This finding suggests that sampling biopsies from
multiple metastatic sites could be beneficial to optimise individua-
lised treatment.
Several HER2 resistance mechanisms has been proposed, such
as mutated PIK3CA, PTEN loss or increased AKT and S6K
phosphorylation in breast cancer treatment (Nagata et al, 2004;
Berns et al, 2007; Kataoka et al, 2010), expression of truncated
p95HER2 variant, as found in high-grade endometrial tumours
(Growdon et al, 2015; Carvajal-Hausdorf et al, 2017) and activation
of alternative pathways including other HER family members
(Sergina et al, 2007; Pandya et al, 2011). These findings, in addition
to our discovery that HER2 expression levels decreases in the
metastases may explain some of the challenges with primary
trastuzumab resistance found in endometrial cancer (Diver et al,
2015). Altogether, this knowledge should motivate the set-up of
clinical trials combining HER2-inhibitors with other agents such as
PI3K or mTOR inhibitors affecting downstream parts of the
signalling pathway, and the use of, for example, lapatinib or
afatinib. Suggested approaches to overcome HER2 resistance are
mainly unexplored (Lheureux and Oza, 2016), and combination
therapy-targeting cancer cells simultaneously at multiple check-
points may prove successful in treatment of HER2-positive
endometrial cancer.
Amplifications in ERBB2 have been linked to the effects of
HER2-targeting agents such as the monoclonal antibodies
trastuzumab, pertuzumab and lapatinib in breast cancer (Loibl
and Gianni, 2016). We find a fair level of concordance between
HER2 IHC results and ERBB2 CISH results. Yet a comparison
showed that many metastatic lesions express high HER2 protein
levels (3þ ) without amplification. The HercepTest criteria were
more sensitive (99%) in detecting ERBB2 amplifications than the SI
criteria. Still, a specificity of 88% yields a high level of false
positives, and to ensure valid assessment of ERBB2 amplification
status in metastatic endometrial cancer, CISH or fluorescent in situ
hybridisation (FISH) should be preferred.
In serous endometrial carcinomas, the ERBB2 amplification
status has been found to be heterogeneous (Buza and Hui, 2013)
and the ASCO/CAP criteria (430% cell stained) have been found
to correspond better with FISH as compared with the HercepTest
(410% cell stained) (Buza et al, 2013). Combined with our
findings this could imply that the ideal cutoff for stained cells could
lie B 30% in endometrial cancer, at least for serous tumours. To
improve reliability of HER2 scoring in endometrial cancer, both
scoring method and staining patterns should be further investi-
gated in future studies.
True ERBB2 amplified tumours are believed to be HER2 driven,
and could be potential targets for monoclonal HER2-targeting
antibodies. Recently, antibody-conjugated drugs (ADCs) have
shown promising results even when HER2 is not a tumour driver.
The ADC, trastuzumab emtansine (Genentech/Roche) delivers the
cytotoxic agent emtansine into HER2 expressing cells (Junttila
et al, 2011) and has shown effect in recurrent or metastatic HER2-
positive serous endometrial cancer (Santin et al, 2017). SYD985
(Synthon Biopharmaceuticals BV) show high efficacy in uterine
serous carcinoma mouse xenograft models with both strong (3þ )
and low to intermediate (that is, 1þ /2þ ) HER2 expression (Black
et al, 2016). These results suggest inclusion of endometrial cancer
patients with metastatic tumours with HercepTest Score X2þ
regardless of ERBB2 amplification status. In the present study, the
HercepTest Score X2þ in metastatic serous, clear cell and
carcinosarcomas were 51%, 31% and 29%, respectively. These
patients have poor prognosis, are typically poor responders to
conventional therapy (English et al, 2013) and could be candidates
for HER2-directed ADCs.
A recent study on HER2 in combination with the promising
prognostic biomarker L1CAM in early endometrioid tumours
revealed that HER2-expressing cells further aggravated the a priori
poor prognosis of the L1CAM-positive endometrioid tumours.
Furthermore, double immunostaining revealed a mutually exclu-
sive staining pattern for HER2 and L1CAM on the level of tumour
cells (Abdel Azim et al, 2017). IHC detection of both these two
surface proteins could serve as a diagnostic tool to select patients
with potential benefit from HER2- and/or L1CAM targeting
therapies.
In conclusion, our data confirm that the loss of HER2-positive
status in metastatic lesions may occur in patients with HER2-
positive primary tumours. Tissue sampling of metastatic lesions
may be helpful in optimising therapeutic agents according to the
molecular phenotype of the metastatic disease rather than that of
the primary tumour. We have identified potential subgroups for
HER2-directed treatment of metastatic or recurrent endometrial
cancer, and based on the high level of HER2-positivity when also
including 2þ tumours in metastatic lesions we encourage ADC-
based anti-HER2 approaches in future clinical trials. Still, selection
of potential candidates needs to be based on refined HER2 testing
protocols and preferably testing in multiple full-section metastatic
lesions.
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